NASDAQ:INBX | Free Cash Flow | Inhibrx Biosciences, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2023-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$38.03M$0.00-$38.03M
2025-12-31-$30.12M$0.00-$30.12M
2025-03-31-$35.9M$21,000.00-$35.92M
2024-12-31-$43.72M$16,000.00-$43.74M
2024-03-31-$63.05M$1.12M-$64.17M
2023-12-31-$56.82M$3.44M-$60.26M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$129.79M$31,000.00-$129.83M
2024-12-31-$194.41M$2.6M-$197.01M-11.67%
2023-12-31-$193.31M$4.59M-$197.9M